Travere Therapeutics, Inc. (NASDAQ:TVTX) CAO Sandra Calvin Sells 12,090 Shares

Travere Therapeutics, Inc. (NASDAQ:TVTX) CAO Sandra Calvin sold 12,090 shares of the firm’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $18.30, for a total value of $221,247.00. Following the completion of the sale, the chief accounting officer now owns 54,927 shares in the company, valued at approximately $1,005,164.10. This represents a 18.04 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Travere Therapeutics Stock Performance

Shares of TVTX opened at $18.18 on Tuesday. Travere Therapeutics, Inc. has a 12-month low of $5.12 and a 12-month high of $20.33. The stock has a market cap of $1.42 billion, a P/E ratio of -4.00 and a beta of 0.70. The company has a current ratio of 1.71, a quick ratio of 1.68 and a debt-to-equity ratio of 24.96. The company has a 50-day moving average of $16.85 and a two-hundred day moving average of $11.52.

Travere Therapeutics (NASDAQ:TVTX) last issued its quarterly earnings data on Thursday, October 31st. The company reported ($0.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.71) by $0.01. The firm had revenue of $62.90 million during the quarter, compared to the consensus estimate of $60.87 million. Travere Therapeutics had a negative return on equity of 537.74% and a negative net margin of 172.75%. The company’s quarterly revenue was up 69.6% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.17) EPS. As a group, research analysts predict that Travere Therapeutics, Inc. will post -3.93 EPS for the current fiscal year.

Analysts Set New Price Targets

TVTX has been the topic of a number of research reports. Barclays raised their target price on shares of Travere Therapeutics from $18.00 to $20.00 and gave the stock an “overweight” rating in a research report on Friday, November 1st. Leerink Partners restated an “outperform” rating and issued a $20.00 price objective on shares of Travere Therapeutics in a research report on Tuesday, October 8th. HC Wainwright dropped their target price on Travere Therapeutics from $23.00 to $18.00 and set a “buy” rating on the stock in a research report on Friday, September 27th. JPMorgan Chase & Co. increased their price objective on Travere Therapeutics from $20.00 to $23.00 and gave the stock an “overweight” rating in a research report on Friday, September 13th. Finally, Bank of America boosted their target price on shares of Travere Therapeutics from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, October 9th. Two investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $22.62.

Institutional Trading of Travere Therapeutics

A number of large investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its stake in Travere Therapeutics by 13.6% in the 1st quarter. Vanguard Group Inc. now owns 6,265,829 shares of the company’s stock valued at $48,310,000 after purchasing an additional 750,686 shares during the last quarter. Millennium Management LLC raised its position in shares of Travere Therapeutics by 33.9% in the second quarter. Millennium Management LLC now owns 2,949,335 shares of the company’s stock valued at $24,244,000 after buying an additional 747,406 shares during the last quarter. Assenagon Asset Management S.A. lifted its stake in shares of Travere Therapeutics by 912.5% during the second quarter. Assenagon Asset Management S.A. now owns 2,214,099 shares of the company’s stock valued at $18,200,000 after buying an additional 1,995,419 shares during the period. Emerald Advisers LLC boosted its position in Travere Therapeutics by 19.8% during the third quarter. Emerald Advisers LLC now owns 1,960,659 shares of the company’s stock worth $27,430,000 after acquiring an additional 323,513 shares during the last quarter. Finally, Finepoint Capital LP boosted its holdings in shares of Travere Therapeutics by 0.3% during the third quarter. Finepoint Capital LP now owns 1,782,267 shares of the company’s stock worth $24,934,000 after purchasing an additional 5,539 shares during the last quarter.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.